Skip to main content
. Author manuscript; available in PMC: 2016 Oct 15.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2015 Oct 31;94(2):254–262. doi: 10.1016/j.ijrobp.2015.10.056

Figure 2.

Figure 2

Cumulative incidence of prostate cancer-specific mortality in patients receiving radiation with neoadjuvant-concurrent androgen deprivation therapy, stratified by a detectable end-of-radiation PSA level. Blue curve represents men with an undetectable end-of-radiation PSA level. Red curve represents men with a detectable end-of-radiation PSA level.